Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
Nitisinone has been approved for treatment of alkaptonuria (AKU). Non-invasive biomarkers of joint tissue remodelling could aid in understanding the molecular changes in AKU pathogenesis and how these can be affected by treatment. Serological and urinary biomarkers of type I collagen and II collagen in AKU were investigated in patients enrolled in the randomized SONIA 2 (NCT01916382) clinical study at baseline and yearly until the end of the study (Year 4). The trajectories of the biomarkers over time were observed. After treatment with nitisinone, the biomarkers of type I collagen remodelling increased at Year 1 (19% and 40% increase in CTX-I and PRO-C1, respectively), which was potentially reflected in the higher degree of mobility seen following treatment. The biomarkers of type II collagen remodelling decreased over time in the nitisinone group: C2M showed a 9.7% decline at Year 1, and levels then remained stable over the following visits; CTX-II showed a 26% decline at Year 3 and 4 in the nitisinone-treated patients. Nitisinone treatment induced changes in biomarkers of bone and cartilage remodelling. These biomarkers can aid patient management and deepen our knowledge of the molecular mechanisms of this rare disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 24(2023), 13 vom: 01. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Genovese, Federica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alkaptonuria |
|---|
| Anmerkungen: |
Date Completed 20.07.2023 Date Revised 20.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms241310996 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359469175 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359469175 | ||
| 003 | DE-627 | ||
| 005 | 20231226080936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms241310996 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359469175 | ||
| 035 | |a (NLM)37446173 | ||
| 035 | |a (PII)10996 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Genovese, Federica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2023 | ||
| 500 | |a Date Revised 20.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Nitisinone has been approved for treatment of alkaptonuria (AKU). Non-invasive biomarkers of joint tissue remodelling could aid in understanding the molecular changes in AKU pathogenesis and how these can be affected by treatment. Serological and urinary biomarkers of type I collagen and II collagen in AKU were investigated in patients enrolled in the randomized SONIA 2 (NCT01916382) clinical study at baseline and yearly until the end of the study (Year 4). The trajectories of the biomarkers over time were observed. After treatment with nitisinone, the biomarkers of type I collagen remodelling increased at Year 1 (19% and 40% increase in CTX-I and PRO-C1, respectively), which was potentially reflected in the higher degree of mobility seen following treatment. The biomarkers of type II collagen remodelling decreased over time in the nitisinone group: C2M showed a 9.7% decline at Year 1, and levels then remained stable over the following visits; CTX-II showed a 26% decline at Year 3 and 4 in the nitisinone-treated patients. Nitisinone treatment induced changes in biomarkers of bone and cartilage remodelling. These biomarkers can aid patient management and deepen our knowledge of the molecular mechanisms of this rare disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a alkaptonuria | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a collagen | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Collagen Type I |2 NLM | |
| 650 | 7 | |a nitisinone |2 NLM | |
| 650 | 7 | |a K5BN214699 |2 NLM | |
| 700 | 1 | |a Frederiksen, Peder |e verfasserin |4 aut | |
| 700 | 1 | |a Bay-Jensen, Anne-Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Karsdal, Morten A |e verfasserin |4 aut | |
| 700 | 1 | |a Milan, Anna M |e verfasserin |4 aut | |
| 700 | 1 | |a Olsson, Birgitta |e verfasserin |4 aut | |
| 700 | 1 | |a Rudebeck, Mattias |e verfasserin |4 aut | |
| 700 | 1 | |a Gallagher, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Ranganath, Lakshminarayan R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 13 vom: 01. Juli |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:13 |g day:01 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms241310996 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 13 |b 01 |c 07 | ||